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Tumor-derived vascular endothelial growth factor (VEGF) has previously been identiﬁed as a causative factor in the disturbed
diﬀerentiation of myeloid dendritic cells (DC) in advanced cancer patients. Here, we investigated the potential of vascular en-
dothelial growth factor receptor (VEGFR) tyrosine kinase (TK) inhibition to overcome this defective DC diﬀerentiation. To this
end, peripheral blood DC (PBDC) precursor and subset frequencies were measured in 13 patients with advanced cancer before
and after treatment with AZD2171, a TK inhibitor (TKI) of VEGFR, coadministered with geﬁtinib, and an epidermal growth fac-
tor receptor (EGFR) TKI. Of note, not only myeloid DC but also plasmacytoid DC frequencies were signiﬁcantly reduced in the
blood of the cancer patients prior to treatment, as compared to healthy controls. Moreover, besides an accumulated population of
immaturemyeloidcells(ImC),apopulation ofmyeloidsuppressorcells (MSC)was signiﬁcantlyincreased.UponsystemicVEGFR
TK inhibition, DC frequencies did not increase, whereas the rate of circulating MSC showed a slight, but not signiﬁcant, decrease.
In conclusion, TK inhibition of VEGFR with AZD2171 does not restore the defective PBDC diﬀerentiation observed in advanced
cancer patients.
Copyright © 2007 H. van Cruijsen et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
1. INTRODUCTION
Defective dendritic cell (DC) diﬀerentiation, maturation,
and functionality are possible mechanisms underlying im-
paired antitumor immunity in cancer patients [1]. DCs play
a central role in the immune system as powerful antigen-
presenting cells, and are essential for the induction of tumor-
speciﬁcT-cell-mediatedimmuneresponses[2].Incancerpa-
tients, the frequencies of circulating DCs are signiﬁcantly
lower as compared to healthy individuals [3–5]. Accumu-
lation of immature myeloid cells (ImC) and functionally
impaired DCs has been documented in blood, tumors,
and tumor-draining lymph nodes and found to be a poor
prognostic factor [3, 4, 6]. Preclinical studies show that
tumor-induced inhibition of DC diﬀerentiation is mediated
by tumor-derived soluble factors such as IL-10, IL-6, M-
CSF, prostaglandins, and vascular endothelial growth factor
(VEGF) [7–11].
VEGF, produced by most tumors, is a strong inhibitor
of myeloid DC diﬀerentiation in vitro [7]a n da ﬀects the
early stages of functional DC diﬀerentiation [12, 13]. High-
systemic VEGF levels, present in most cancer patients, cor-
relate with low DC frequencies [3, 4], while abnormally el-
evated numbers of immature DC precursors reportedly de-
creasedinthreeoutofthreecancerpatientsduringtreatment
with the anti-VEGF antibody bevacizumab [3].
VEGF is also one of the most important proangio-
genic molecules and induces proliferation, diﬀerentiation,
and migration of endothelial cells in tumors. Over the past
decades, many trials with inhibitors of angiogenesis have2 Clinical and Developmental Immunology
beenconductedandhaveresultedintheregistrationofbeva-
cizumab as an anticancer therapy [14]. VEGF exerts its eﬀect
via binding to three tyrosine kinase (TK) receptors, VEGFR-
1, -2, and -3, which are mainly, but not exclusively, present
on endothelial cells (VEGFR-1, and -2) and lymphatic en-
dothelium (VEGFR-3) [15]. Blocking VEGF signaling by in-
hibiting TK activity of its receptor, is a promising anticancer
strategy. AZD2171 is a novel potent inhibitor of VEGFR-2
kinase activity, with additional activity against VEGFR-1 and
-3 [16].
Currently, AZD2171 is being evaluated in clinical tri-
als as an oral anticancer agent with antiangiogenic eﬀects
in a variety of solid tumors. To further investigate the rela-
tionship between VEGFR signaling and DC diﬀerentiation,
we evaluated the eﬀect of administration of the VEGFR in-
hibitor AZD2171 on peripheral blood DC (PBDC) subsets
in advanced cancer patients. To our knowledge, this is the
ﬁrst study to monitor DC subsets in the blood of cancer
patients who are treated with a VEGFR tyrosine kinase in-
hibitor (TKI).
2. MATERIAL AND METHODS
2.1. Patientsandhealthydonors
Between May 2004 and December 2004, 13 patients of the
VU Medical Center, Amsterdam, were selected to participate
in a phase I study combining AZD2171 (AstraZeneca, Wilm-
ington, DE, USA) a VEGFR TKI [16], with geﬁtinib (As-
traZeneca, Wilmington DE), a TKI of the epidermal growth
factor receptor (EGFR). The dose of AZD2171 was escalated
in small, consecutive cohorts of advanced cancer patients
coadministered with 250mg geﬁtinib in order to establish
a maximum-tolerated dose. Thirteen patients (three women
and ten men) were included in one of the three-AZD2171
dosing cohorts: 20mg (n = 3), 30mg (n = 7), and 45mg (n
= 3). Major inclusion criteria were locally advanced or dis-
seminated disease, which was refractory to standard therapy,
a g eo v e r1 8y e a r s ,a n dap e r f o r m a n c es t a t u so f0 – 2 .E x c l u d e d
were patients with impaired renal or liver function or inad-
equate bone marrow reserve. The clinical trial was approved
by the Medical Ethical Committee, and after obtaining in-
formed consent, blood from the patients (mean age of 52,
range from 31 to 66) was drawn before treatment and after
fourorﬁveweeksofdailyoraldosingofbothdrugs(depend-
ing on the dosing schedule of the protocol). A variety of pri-
marytumorswasrepresented:coloncancer(n=3),mesothe-
lioma (n = 2 ) ,m e l a n o m a( n = 2), ﬁbrosarcoma, osteosar-
coma, renal cell cancer, cervical cancer, pancreas cancer, and
NSCLC (all n = 1). After four or ﬁve weeks of treatment, tu-
mor status was evaluated according to RECIST [17].
Two control groups were included. First, blood was
drawn from nine age- and sex-matched healthy donors (two
women and seven men, mean age of 47, range from 32 to 55)
to collect peripheral blood mononuclear cells (PBMCs). A
second control group consisted of four advanced non-small
cell lung cancer (NSCLC) patients (a woman and three men,
mean age of 61, range from 51 to 66) who received geﬁtinib
monotherapy. PBMCs were obtained at baseline and four
weeks after daily dosing of 250mg geﬁtinib.
2.2. PBDCmonitoring
PBMCs were isolated by Ficoll density-gradient centrifuga-
tion (Lymphoprep, Oslo, Norway) within 24 hours of blood
sampling. FACS analysis (Becton Dickinson, Franklin Lakes,
NJ, USA) was performed to measure peripheral blood DC
(PBDC) subset frequencies and their maturation status us-
ing four-color staining with antibodies directly conjugated
with ﬂuorochromes FITC, PE, PerCP-Cy5, or APC. Mono-
clonal antibodies against the following markers were used:
CD3, CD11c, CD14, CD19, CD56, CD86, CD123, EGFR,
HLA-DR (all BD Biosciences, San Jose, CA, USA), BDCA-
1, BDCA-2, BDCA-3, BDCA-4 (all Miltenyi Biotec GmbH,
Bergisch Gladbach, Germany), VEGFR-1, VEGFR-2 (R&D
Systems, Minneapolis, MN, USA), and CD33 (Immunotech,
Marseille, France). A gate was set on the population contain-
ing lymphocyte and monocytes, based on the forward and
sideward scatter plots to avoid erythrocytes, cell debris, and
neutrophil contamination.
Datawereobtainedfromaminimumof150.000cellsand
were analyzed using CellQuest software (Macintosh). Results
are shown as percentages of the total number of PBMCs.
Labeled isotype-matched IgG antibodies were used to de-
termine background ﬂuorescence in each analysis. Median
ﬂuorescence indices were calculated by dividing the median
expression of the antibody of interest by the median back-
ground ﬂuorescence as determined by the isotype-matched
IgG antibody.
Diﬀerent PBDC precursor populations and subsets were
studied, reﬂecting diﬀerent stages of development (schemat-
ically presented for the myeloid lineage in Figure 1).
MyeloidDC(MDC)
Immaturemyeloidcells(ImC),previouslyidentiﬁedasMDC
or macrophage precursors in varying stages of diﬀerentia-
tion [18], were deﬁned as positive for CD11c, but negative
for the lineage (Lin) markers CD3 (T cells), CD14 (mono-
cytes), CD19 (B cells), and CD56 (NK cells), as well as for
HLA-DR as previously described [3]. More mature MDC
precursors(pMDC)weredeﬁnedasCD11chi Lin−HLA-DR+,
and the frequencies of two MDC subsets contained within
this population were more speciﬁcally determined based on
the expression of blood DC antigen (BDCA) markers: DCs
belonging to the so-called myeloid DC subset 1 (MDC-1)
were identiﬁed as CD11chi, CD14
−, and BDCA-1/CD1c+,




PDCs were detected as CD11c
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−, CD123hi,a n d
BDCA-2+,o ra sL i n −BDCA4+. As previously described, in
blood, both BDCA-2 and BDCA-4 are exclusively expressed
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Figure 1: A model of myeloid dendritic cell diﬀerentiation under cancer conditions, in which tumor-derived factors exert their inhibitory
eﬀect at the stage of immature Lin−CD11c+ HLA-DR− myeloid cells (ImCs), blocking their diﬀerentiation into mature myeloid DC precur-
sors (pMDC), while, simultaneously, skewing their diﬀerentiation towards a population of CD14+ HLA-DRneg/low myeloid suppressive cells
(MSCs). HPCs: hematopoietic cells; Lin: lineage markers (CD3, CD14, CD19, and CD56); MDC: myeloid dendritic cell.
Table 1: Expression of CD86 and HLA-DR on PBDC subsets.a
PBDC subset pMDC MDC-1 MDC-2 PDC
HLA-DR CD86 HLA-DR CD86 HLA-DR CD86 HLA-DR
Healthy donorsb 60.4 18.4 802 5.4 517.1 2.5 295.7
(7.3–274.8) (7.2–31.6) (403.3–1471.6) (3.0–6.4) (196.4–1251.4) (1.3–3.5) (165.6–469.7)
Cancer patients,c
predose
63.9 17.5 650.4 10.4 317.5 2.6 253.6
(19.9–212.4) (7.7–55.5) (166.2–1028.1) (2.3–41.4) (46.9–854.5) (1.2–3.3) (61.8–528.6)
Cancer patients,
postdosed
51.9 13.1 495.3 7.5 264.2 2.5 251.2
(26.2–134.1) (7.9–33.7) (264.2–842.6) (2.2–11.0) (139.6–395.8) (1.6–4.0) (123.6–427.4)
aMean and range of median ﬂuorescence index are listed.
bHealthy donors, n = 8
cCancer patients, n = 13
dPostdose, after 4-5 weeks of VEGFR inhibition.
2.3. MeasurementofcirculatingVEGF
At the time of PBMC isolation, serum samples were also col-
lected. After clot formation (60 minutes at room temper-
ature) and centrifugation, serum was harvested and stored
at −80◦C. Circulating VEGF levels were measured in serum
samples with a Quantikine ELISA kit (R&D systems, Min-
neapolis, MN, USA), following the manufacturer’s instruc-
tions.
2.4. Statisticalanalysis
Since we could not assume a normal distribution of the DC
subset frequencies, we applied nonparametric tests. Percent-
ages of PBDCs and levels of circulating VEGF obtained from
samples during VEGFR TK inhibition were compared with




data. Diﬀerences were considered to be statistically signiﬁ-
cant when P<. 05.
3. RESULTS
Thirteen patients included in the phase I study combining
AZD2171 with geﬁtinib participated in the DC monitoring
study. Preliminary eﬃcacy of treatment was observed in four
patients. In one patient, a partial remission was observed; in
three patients a decrease in tumor size was noticed, but this
decrease did not reach the criteria for partial remission and
was considered a stable disease.4 Clinical and Developmental Immunology
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mesothelioma. Events are gated for the absence of Lin marker expression and the presence of CD33 expression. Lin− cells, that is, immature
myeloid cells (ImCs) and more mature MDC precursors (pMDC), were distinguished from plasmacytoid dendritic cells (PDC) by BDCA-4
expression (a). CD33 expression was determined for the CD11chi HLA-DR+ population. Within the HLA-DR positive population (pMDC),
two subpopulations (A and B) were discernable based on intermediate and high CD33 expression (a). Results for immature myeloid cells
(ImC and Lin− HLA-DR−) (b) and mature MDC precursors (pMDC and Lin− CD33hi HLA-DRhi) (c) are shown for healthy donors and for
cancer patients before (predose) and after VEGFR inhibition (postdose) (c). Peripheral blood DC percentages are of total peripheral blood
mononuclear cells. In both graphs, individual values and the means are shown.
3.1. VEGFR-1,VEGFR-2,andEGFRexpressionon
thestudiedPBDCsubsets
Diﬀerent PBDC precursor populations and subsets were
studied, reﬂecting diﬀerent stages of development, as de-
scribed in “Materials and Methods” section (see also
Figure 1). To establish the ImC and pMDC and the MDC
and PDC subsets as viable targets for the employed VEGFR
and EGFR TKIs, expression levels of VEGFR-1, VEGFR-2,
and EGFR were determined and expressed by their median
ﬂuorescence indices (med FI). Both VEGFR-1 and VEGFR-
2 were expressed, albeit at generally low levels, on ImC and
on pMDC (med FI range from 2.1 to 3.1), as well as on the
MDC-1,MDC-2,andPDCsubsets(medFIrangefrom2.0to
3.8). In contrast, EGFR was not expressed on any of the stud-






Almand et al. [3]reported an accumulation of imma-
ture Lin−HLA-DR− ImC in the blood of cancer patients,
whilemorematureLin −HLA-DR+MDCprecursors(pMDC)
were found to be reduced. To further characterize theseH. van Cruijsen et al. 5
Patient






















































p = 0.005 p = 0.08
(b)
Figure 3: Results for myeloid suppressor cells (CD14+ HLA-DRneg/low) in healthy donors and in cancer patients before and after VEGFR
inhibition. Typical results of myeloid suppressor cells in a patient and one healthy donor are shown (a). Peripheral blood DC percentages are
of total peripheral blood mononuclear cells. The individual values and the means for healthy donors and cancer patients before (predose)
and after VEGFR TKI inhibition (postdose) are shown (b).
populations, we included the myeloid lineage-associated
markers CD11c and CD33. BDCA-4 (neuropilin-1, ex-
pressed by PDC) was included in our analyses to ascertain if
the previously reported accumulation of immature DC pre-
cursors contained within the Lin−DR−ImC fraction might
actually involve PDCs. Typical results, shown in Figure 2(a),
demonstrate that the Lin−HLA-DR− ImC were CD11c+ and
did not express BDCA-4, and were, therefore, unlikely to in-
clude PDCs. In Figure 2(a), CD33 expression is shown for
the Lin−CD11chi HLA-DR+ pMDC population. Within this
pMDC population, twosubpopulations wereclearlydiscern-
able based on diﬀerent CD33 expression levels (indicated as
Aa n dBi nFigure 2(a)). As CD33 is a myeloid marker known
to be associated with PBDC diﬀerentiation and previously
shown to be highly expressed on the MDC-1 and MDC-2
subsets but not on an immature DC progenitor subset [20],
we take this CD33hi population to represent a more mature
MDC population.
We did observe a slight accumulation of ImC in the ad-
vanced cancer patients (based on pretreatment frequencies),
but this did not reach the level of signiﬁcance when com-
pared to healthy donors (Figure 2(b)). Of note, within the
pMDC population, cells with high CD33 expression levels
(population B in Figure 2(a)) were signiﬁcantly decreased
in the cancer patients before treatment, as compared to the
healthy donors (P = .02, Figure 2(c)). In the cancer patients,
VEGFR TK inhibition through AZD2171 treatment did not
signiﬁcantly change the frequencies of the MDC precur-
sors in any of these diﬀerent stages of development (Figures
2(b), 2(c)). Of note, Figure 2(c) shows three outlying post-
dose pMDC frequencies well above the mean of the postdose
cancer patient group. In conjunction with a restoration of
pMDC frequencies to values within the range observed for
healthy donors, thesethree patients experienced clinical ben-
eﬁt from AZD2171 and geﬁtinib treatment: two patients had
aminorresponseandthethirdpatienthadstablediseaselast-
ing for 31 weeks.
3.2.2. Myeloidsuppressorcells(MSC)
We identiﬁed a population of CD14+HLA-DRneg/low cells in
the blood of our patients (Figure 3(a)), which, before treat-
ment, was signiﬁcantly increased as compared to healthy
donors (P = .005, Figure 3(b)). A recent report suggests that
these so-called myeloid suppressor cells (MSC) exert im-
munosuppressive eﬀects via secretion of cytokines including
a transforming growth factor (TGF)-β [21]. Hypothetically,
these MSC may derive from ImC accumulating due to dis-
turbed DC diﬀerentiation (see Figure 1) .A f t e rf o u rt oﬁ v e
weeks of treatment with AZD2171, MSC frequencies in the
cancer patients went down, although not signiﬁcantly (P =
.08, Figure 3(b)). Of note, normalization upon VEGFR TK
inhibitionofextremelyhighpredoseMSCfrequenciesintwo
patients(clearoutliersof>2%ofPBMCsinFigure 3(b))was
in both cases followed by a minor clinical response.
3.2.3. Myeloid(MDC-1andMDC-2)andplasmacytoid
(PDC)DCsubsets
Typical pretreatment FACS data for MDC-1 (BDCA-
1/CD1c+), MDC-2 (BDCA-3/CD141+), and PDC (BDCA-
2/CD303+) from one patient are shown in Figure 4,n e x tt o
comparable data from a healthy donor. Pretreatment MDC
subset frequencies in the mononuclear cell population were
signiﬁcantly lower in the blood of cancer patients as com-
pared to healthy donors (MDC-1: patients 0.19 ± 0.10%
[mean ± SD] versus controls 0.39 ± 0.11%, P = .002; MDC-
2: patients 0.019 ± 0.01% versus controls 0.04 ± 0.01%,
P =.001;Figures4(g),4(h)).Ofnote,PDCfrequenciesinthe
blood of the cancer patients were also signiﬁcantly decreased
(patients0.19±0.15%versuscontrols0.31±0.10%;P =0.04;
Figure 4(i)). Treatment with AZD2171 did not raise the fre-
quencies of the MDC-1, MDC-2, or PDC subsets in patients
with advanced cancer (Figures 4(g)–4(i)).6 Clinical and Developmental Immunology
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Figure 4: Typical results of peripheral blood DC monitoring based on BDCA marker analysis of a patient with ﬁbrosarcoma (a, c, e) and
one healthy donor (b, d, f). Plots for MDC-1 (BDCA-1/CD1c+ (a, b)), MDC-2 (BDCA-3/CD141+ (c, d)), and PDC (BDCA-2/CD303+ (e,
f)) are shown. In all plots, peripheral blood DC percentages are of total peripheral blood mononuclear cells and based on the absence of
CD14 expression. MDC-1 frequencies in healthy donors and in cancer patients before (predose) and after VEGFR inhibition (postdose)
(g), MDC-2 frequencies in healthy donors and in cancer patients before (predose) and after VEGFR inhibition (postdose) (h), and PDC
frequencies in healthy donors and in cancer patients before (predose) and after VEGFR inhibition (postdose) (i) are shown. Peripheral
blood DC percentages are of total peripheral blood mononuclear cells. In all graphs, individual values and the means are shown.H. van Cruijsen et al. 7
Absolute numbers of the measured DC subsets per mL
of blood were also calculated, and these numbers were
not signiﬁcantly aﬀected by the TKI therapy either (data
not shown). Apart from the anecdotal observations for the
pMDC and MSC discussed above, no further correlations
could be established between the dose of AZD2171 or the
tumor response and the measured ImC, PBDC, or MSC fre-
quencies.
Since patients received daily dosing of both AZD2171
and250mggeﬁtinib,wealsoincludedfouradvancedNSCLC
patients receiving 250mg geﬁtinib monotherapy to distin-
guish between any eﬀects of VEGFR and EGFR inhibition.
GeﬁtinibmonotherapydidnotaﬀectthePBDCnortheMSC
frequencies in the blood of the studied cancer patients (data
not shown), consistent with the observed lack of EGFR ex-
pression on these cell populations.
3.3. PBDCmaturationstatusbeforeand
afterVEGFRTKinhibition
To assess the maturation status of the pMDC, MDC, and
PDC subsets before and after VEGFR TK inhibition, expres-
sion levels of CD86 and/or HLA-DR were determined. Me-
dian ﬂuorescence indices for healthy donors and cancer pa-
tients are listed in Table 1. No signiﬁcant diﬀerences in CD86
and/or HLA-DR expression levels on the pMDC, MDC, and
PDC subsets were found between healthy volunteers (n = 8)
and tested cancer patients (n = 13), neither before nor after
treatment with AZD2171.
3.4. CirculatingVEGFlevels
To correlate the levels of tumor-derived VEGF to PBDC fre-
quencies, serum levels of VEGF were measured. We mea-
sured 2-fold higher levels of serum VEGF in the cancer pa-
tients at baseline than previously reported in healthy donors
[22]. Interestingly, serum VEGF levels in cancer patients
tended to increase after four to ﬁve weeks of treatment with
AZD2171 and geﬁtinib with a mean pretreatment VEGF
level of 626pg/ml (range from 114 to 2847pg/ml) and a
mean posttreatment level of 947pg/ml (range from 245 to
3360pg/ml; P = .2). VEGFR TK inhibition is known to up-
regulate circulating VEGF levels, which has previously been
demonstrated for multiple VEGFR TK inhibitors [23, 24]. In
our studies, no correlation was found between serum VEGF
levels and ImC, PBDC, or MSC frequencies, neither before
nor after treatment. In addition, no correlation was observed
between serum VEGF levels and clinical outcome.
4. DISCUSSION
Since VEGF has been shown to block DC diﬀerentiation and
maturationinpreclinicalmodels,highlevelsofVEGFincan-
cer patients may induce an accumulation of immature and
functionallyimpairedDCcontributingtotumorescapefrom
immunosurveillance. As indicated in Figure 1 and based on
previous reports [3], we hypothesized that tumor-derived
VEGF might exert its inhibitory eﬀect at the stage of im-
mature HLA-DR−MDC precursors within the ImC fraction
blocking their development into pMDC, while simultane-
ouslyskewingtheirdiﬀerentiationtowardsanewlyidentiﬁed
populationofmyeloidCD14+HLA-DRneg/low suppressorcells
with immunosuppressive traits [21].
We, therefore, evaluated the eﬀect of administration of
the VEGFR TKI AZD2171 on PBDC precursor and subset
frequencies in advanced cancer patients. It is important to
keep in mind that conclusions drawn from this study may
be hampered by the applied phase I study design, including
multiple dose levels and a heterogeneous patient population.
Nevertheless, we found an increased number of immature
DC precursors in cancer patients, although this diﬀerence
didnotreachthelevelofsigniﬁcance.Wealsoidentiﬁedasig-
niﬁcantly increased number of CD14+HLA-DRneg/low MSC
inthebloodofcancerpatientsascomparedtohealthydonors
(P = .005), which tended to be lower after four or ﬁve weeks
of VEGFR inhibition. Furthermore, we found that the fre-
quencies of pMDCs, including MDC-1 and MDC-2, were
signiﬁcantly reduced in advanced cancer patients as com-
pared to healthy individuals. In addition, PDC frequencies
were signiﬁcantly reduced in cancer patients compared to
healthy donors as previously reported for patients with Ka-
posi sarcoma or advanced prostate cancer [25, 26]. These re-
sults point to a generalized defective DC diﬀerentiation, in-
volving multiple DC lineages, across a variety of diﬀerent tu-
mor types. Thus the eﬀect of advanced tumors on DC dif-
ferentiation is systemic and results in a profound reduction
of mature DC precursors in the circulation and a simultane-
o u sa c c u m u l a t i o no fi m m a t u r em y e l o i dD Cp r e c u r s o r sw i t h
a potentially immunosuppressive role (Figure 1), in line with
previous reports [3, 4, 6]. After a period of four to ﬁve weeks
of AZD2171 administration, we did not observe an overall
signiﬁcant increase in pMDC (or indeed, PDC) frequencies,
nor did we observe a diﬀerence between CD86 and/or HLA-
DR expression levels on pMDCs and PBDCs in cancer pa-
tients versus healthy donors. This is in contrast to earlier
ﬁndings by Almand et al. [3] ,w h or e p o r t e dal o w e re x p r e s -
sion of costimulatory molecules on immature myeloid cells.
Might the duration and dosing of AZD2171 adminis-
tration have been insuﬃcient to eﬀect a reversal of the ob-
served systemic DC diﬀerentiation? A period of four or ﬁve
weeks of AZD2171 administration should be suﬃcient to af-
fect PBDC frequencies, since frequencies of DC precursors
were reported to improve already three to four weeks after
tumor resection [3, 5]. Although it remains to be formally
proven that AZD2171 actually inhibits the phosphorylation
of VEGFR on PBMCs, pharmacokinetic data show that, af-
ter multiple daily dosages of 20, 30, or 45mg of AZD2171,
biologically active plasma concentrations are reached, suﬃ-
cient for sustained VEGFR-1, -2, and -3 inhibition with sub-
sequent eﬀects on clinical parameters, for example, a clear
rise in blood pressure [23]. Furthermore, the pharmacoki-
netics of AZD2171 was not aﬀected by coadministration of
geﬁtinib (van Cruijsen et al., Proceedings of the 41st annual
meetingoftheAmericanSocietyofClinicalOncology,2005).
Rather than by these pharmacodynamic or kinetic consid-
erations, the lack of eﬀect on PBDC frequencies of VEGFR
TK inhibition in our study may be explained by the ad-
vanceddiseasestateoftheparticipatingpatients,whichlikely8 Clinical and Developmental Immunology
resulted in a redundancy of DC suppressive factors. Besides
VEGF,othercytokinessecretedbytumorcellsareinvolved in
the inhibition of DC diﬀerentiation and maturation, among
others areIL-6, IL-10, and M-CSF [27–29]. These other sol-
uble tumor-derived factors may thus overrule the potentially
beneﬁcial eﬀect of VEGFR signaling blockade, particularly
in late stages of cancer development, which are associated
with relatively high systemic levels of these suppressive fac-
tors. VEGF may also exert its eﬀect on DC diﬀerentiation
via another mechanism unlike phosphorylation of VEGFR
on DC [30, 31]. A small trial using bevacizumab (a mon-
oclonal antibody binding and neutralizing VEGF) in combi-
nation withchemotherapydid report improved DCfrequen-
cies after treatment [3]. These results, which are in contrast
to our ﬁndings using AZD2171, a TKI of VEGFR, might in-
dicate an indirect, TK-independent eﬀect of VEGF on DC
diﬀerentiation.
Although we did not observe an eﬀect of VEGFR TK in-
hibition on PBDC precursors and subsets in cancer patients,
the frequencies of accumulated MSCs tended to decrease
after AZD2171 treatment. This CD14+HLA-DRneg/low MSC
population may be the human equivalent of CD11b+and Gr-
1myeloidsuppressivecellsidentiﬁedinmice[32,33],andwe
hypothesized that tumor-derived VEGF might have skewed
the hematopoiesis towards an expansion of these myeloid
cellswithimmunosuppressivetraits.Inmice,thisscarcepop-
ulation of immunosuppressive cells could be increased by
tumor-derived factors while neutralizing VEGF-antibodies
inhibited expansion of this myeloid subset [34]. Reduction
of MSC in murine models has been shown to facilitate the
rejection of established metastatic disease [35]. It is notable,
in this regard, that both the two patients with high pretreat-
ment MSC frequencies, which normalized upon VEGFR TKI
administration, had a minor clinical response. One of these
alsoshowedasimultaneousincreaseinpMDCtonormallev-
els. However, due to the nature and size of this Phase I trial,
these clinical observations remained anecdotal.
Ideally, phenotypic analyses of MSC and PBDC precur-
sorsandsubsetsshouldbeaccompaniedbyfunctionalassays.
Large volumes of blood would have been needed to evalu-
ate the eﬀect of AZD2171 on PBDC function, which made
this an unfeasible approach in the current setting. Additional
in vitro studies are, therefore, ongoing to assess the eﬀect of
VEGFR TK inhibition on DC and MSC diﬀerentiation and
functionality.
In conclusion, our results indicate that advanced cancer
patients harbor increased immature myeloid DC precursor
and MSC frequencies, both with potential immunosuppres-
sive eﬀects, as well as reduced MDC and PDC frequencies
in their circulation. VEGFR TK inhibition by AZD2171 with
antiangiogenicandpreliminaryanticancereﬀectsdidnotap-
pear to change any of these DC (precursor) frequencies, al-
though a trend was observed towards reduced MSC frequen-
cies. Our results support the idea that tumor-induced inhibi-
tion of DC diﬀerentiation is systemic and most likely caused
by multiple factors. Clinical approaches to reverse this pro-
cess should, therefore, encompass systemic blockade of addi-
tional tumor-derived immunosuppressive cytokines besides
VEGF.
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